Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model

Christy A. Rothermund, Velliyur K. Gopalakrishnan, James D Eudy, Jamboor K. Vishwanatha

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The changes in gene expression profile as prostate cancer progresses from an androgen-dependent disease to an androgen-independent disease are still largely unknown. Methods: We examined the gene expression profile in the LNCaP prostate cancer progression model during chronic treatment with Casodex using cDNA microarrays consisting of 2305 randomly chosen genes. Results: Our studies revealed a representative collection of genes whose expression was differentially regulated in LNCaP cells upon treatment with Casodex. A set of 15 genes were shown to be highly expressed in Casodex-treated LNCaP cells compared to the reference sample. This set of highly expressed genes represents a signature collection unique to prostate cancer since their expression was significantly greater than that of the collective pool of ten cancer cell lines of the reference sample. The highly expressed signature collection included the hypoxia-related genes membrane metallo-endopeptidase (MME), cyclin G2, and Bcl2/adenovirus E1B 19 kDa (BNIP3). Given the roles of these genes in angiogenesis, cell cycle regulation, and apoptosis, we further analyzed their expression and concluded that these genes may be involved in the molecular changes that lead to androgen-independence in prostate cancer. Conclusion: Our data indicate that one of the mechanisms of Casodex action in prostate cancer cells is induction of hypoxic gene expression.

Original languageEnglish (US)
Article number5
JournalBMC Urology
Volume5
DOIs
StatePublished - Mar 24 2005

Fingerprint

Prostatic Neoplasms
Gene Expression
Androgens
Genes
Transcriptome
Cyclin G2
Neprilysin
Oligonucleotide Array Sequence Analysis
Adenoviridae
Cell Cycle
bicalutamide
Hypoxia
Apoptosis
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Reproductive Medicine

Cite this

Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. / Rothermund, Christy A.; Gopalakrishnan, Velliyur K.; Eudy, James D; Vishwanatha, Jamboor K.

In: BMC Urology, Vol. 5, 5, 24.03.2005.

Research output: Contribution to journalArticle

Rothermund, Christy A. ; Gopalakrishnan, Velliyur K. ; Eudy, James D ; Vishwanatha, Jamboor K. / Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. In: BMC Urology. 2005 ; Vol. 5.
@article{d71e39c26d334ad88ef72a6c0d40245e,
title = "Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model",
abstract = "Background: The changes in gene expression profile as prostate cancer progresses from an androgen-dependent disease to an androgen-independent disease are still largely unknown. Methods: We examined the gene expression profile in the LNCaP prostate cancer progression model during chronic treatment with Casodex using cDNA microarrays consisting of 2305 randomly chosen genes. Results: Our studies revealed a representative collection of genes whose expression was differentially regulated in LNCaP cells upon treatment with Casodex. A set of 15 genes were shown to be highly expressed in Casodex-treated LNCaP cells compared to the reference sample. This set of highly expressed genes represents a signature collection unique to prostate cancer since their expression was significantly greater than that of the collective pool of ten cancer cell lines of the reference sample. The highly expressed signature collection included the hypoxia-related genes membrane metallo-endopeptidase (MME), cyclin G2, and Bcl2/adenovirus E1B 19 kDa (BNIP3). Given the roles of these genes in angiogenesis, cell cycle regulation, and apoptosis, we further analyzed their expression and concluded that these genes may be involved in the molecular changes that lead to androgen-independence in prostate cancer. Conclusion: Our data indicate that one of the mechanisms of Casodex action in prostate cancer cells is induction of hypoxic gene expression.",
author = "Rothermund, {Christy A.} and Gopalakrishnan, {Velliyur K.} and Eudy, {James D} and Vishwanatha, {Jamboor K.}",
year = "2005",
month = "3",
day = "24",
doi = "10.1186/1471-2490-5-5",
language = "English (US)",
volume = "5",
journal = "BMC Urology",
issn = "1471-2490",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model

AU - Rothermund, Christy A.

AU - Gopalakrishnan, Velliyur K.

AU - Eudy, James D

AU - Vishwanatha, Jamboor K.

PY - 2005/3/24

Y1 - 2005/3/24

N2 - Background: The changes in gene expression profile as prostate cancer progresses from an androgen-dependent disease to an androgen-independent disease are still largely unknown. Methods: We examined the gene expression profile in the LNCaP prostate cancer progression model during chronic treatment with Casodex using cDNA microarrays consisting of 2305 randomly chosen genes. Results: Our studies revealed a representative collection of genes whose expression was differentially regulated in LNCaP cells upon treatment with Casodex. A set of 15 genes were shown to be highly expressed in Casodex-treated LNCaP cells compared to the reference sample. This set of highly expressed genes represents a signature collection unique to prostate cancer since their expression was significantly greater than that of the collective pool of ten cancer cell lines of the reference sample. The highly expressed signature collection included the hypoxia-related genes membrane metallo-endopeptidase (MME), cyclin G2, and Bcl2/adenovirus E1B 19 kDa (BNIP3). Given the roles of these genes in angiogenesis, cell cycle regulation, and apoptosis, we further analyzed their expression and concluded that these genes may be involved in the molecular changes that lead to androgen-independence in prostate cancer. Conclusion: Our data indicate that one of the mechanisms of Casodex action in prostate cancer cells is induction of hypoxic gene expression.

AB - Background: The changes in gene expression profile as prostate cancer progresses from an androgen-dependent disease to an androgen-independent disease are still largely unknown. Methods: We examined the gene expression profile in the LNCaP prostate cancer progression model during chronic treatment with Casodex using cDNA microarrays consisting of 2305 randomly chosen genes. Results: Our studies revealed a representative collection of genes whose expression was differentially regulated in LNCaP cells upon treatment with Casodex. A set of 15 genes were shown to be highly expressed in Casodex-treated LNCaP cells compared to the reference sample. This set of highly expressed genes represents a signature collection unique to prostate cancer since their expression was significantly greater than that of the collective pool of ten cancer cell lines of the reference sample. The highly expressed signature collection included the hypoxia-related genes membrane metallo-endopeptidase (MME), cyclin G2, and Bcl2/adenovirus E1B 19 kDa (BNIP3). Given the roles of these genes in angiogenesis, cell cycle regulation, and apoptosis, we further analyzed their expression and concluded that these genes may be involved in the molecular changes that lead to androgen-independence in prostate cancer. Conclusion: Our data indicate that one of the mechanisms of Casodex action in prostate cancer cells is induction of hypoxic gene expression.

UR - http://www.scopus.com/inward/record.url?scp=17844385811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844385811&partnerID=8YFLogxK

U2 - 10.1186/1471-2490-5-5

DO - 10.1186/1471-2490-5-5

M3 - Article

VL - 5

JO - BMC Urology

JF - BMC Urology

SN - 1471-2490

M1 - 5

ER -